2020-06-03T15:06:19-05:00 2019-12-31 050409384 KAHN LITWIN RENZA & CO LTD 951 NORTH MAIN STREET PROVIDENCE RI 02904 990 2019-01-01 522396428 ALZHEIMER'S DISEASE RESEARCH FOUNDATION D/B/A CURE ALZHEIMER'S FUND ALZH 7812373800 34 WASHINGTON ST NO 310 WELLESLEY HILLS MA 02481 TIMOTHY W ARMOUR PRESIDENT 7812373800 2020-06-03 1 SANDY ROSS P01399337 4012742001 38.111.239.2 2020-06-03 14:34:39 ED P 7BF39E0FC1180629874730249EC20B7A78BA7254 161A28E9BA97D9A68C0A4FE47CB342B6FB9ED543 2019 2020-09-23 17:36:50Z CURE ALZHEIMER'S FUND TIMOTHY W ARMOUR 34 WASHINGTON ST NO 310 WELLESLEY HILLS MA 02481 34576415 0 X WWW. CUREALZ.ORG X 2004 PA TO FUND RESEARCH WITH THE HIGHEST PROBABILITY OF PREVENTING, SLOWING OR REVERSING ALZHEIMER'S DISEASE THROUGH VENTURE BASED PHILANTHROPY WITH ALL ORGANIZATIONAL EXPENSES PAID BY THE BOARD, ALLOWING ALL PUBLIC CONTRIBUTIONS TO DIRECTLY FUND ALZHEIMER'S RESEARCH. 9 8 24 68 0 0 19798072 30497342 0 0 95723 85391 0 0 19893795 30582733 16744506 16351728 0 0 1766370 2117985 0 0 1187877 5118435 5838314 23629311 24308027 -3735516 6274706 7580826 13454870 891589 552268 6689237 12902602 TO FUND RESEARCH WITH THE HIGHEST PROBABILITY OF PREVENTING, SLOWING OR REVERSING ALZHEIMER'S DISEASE THROUGH VENTURE BASED PHILANTHROPY WITH ALL ORGANIZATIONAL EXPENSES PAID BY THE BOARD, ALLOWING ALL PUBLIC CONTRIBUTIONS TO DIRECTLY FUND ALZHEIMER'S RESEARCH. 0 0 19858076 16351728 IN 2019, CURE ALZHEIMER'S FUND SUPPORTED 74 RESEARCH PROJECTS AT 36 LEADING RESEARCH INSTITUTIONS, FOR A FUNDING TOTAL OF MORE THAN $19 MILLION. MANY PROJECTS PURSUED A DEEPER UNDERSTANDING OF THE MECHANISMS OF ACTION OF THE GENES AND VARIANTS WITH THE BIGGEST IMPACT ON RISK AND TIMING OF ALZHEIMER'S DISEASE. OTHER PROJECTS PURSUED NOVEL THEORIES AND TOOLS TO ASSESS POTENTIAL AVENUES FOR PREVENTION AND TREATMENT, IN PARTICULAR REGARDING THE ROLL OF THE BRAIN'S INNATE IMMUNE SYSTEM. ADDITIONAL EXPENSES INCLUDE DEVELOPMENT AND BREEDING OF TRANSGENIC ANIMAL MODELS BY A CONTRACT RESEARCH ORGANIZATION; THE DIRECT SUPPORT OF FACILITATING GRANTS AND THE AWARD PROCESS; AND COSTS ASSOCIATED WITH HOSTING SCIENTIFIC MEETINGS. 2316970 CREATING AWARENESS TOOK THE FORM OF MAILINGS, OUTREACH, AND SUPPORT OF THIRD PARTY EVENTS DESIGNED TO RAISE AWARENESS ABOUT THE NEED OF MORE RESEARCH INTO THE ORIGINS AND PROGRESSION OF ALZHEIMER'S DISEASE. 22175046 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 33 0 24 1 0 0 0 0 0 0 0 0 0 0 0 0 X 9 8 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 MA X X X TIMOTHY W ARMOUR 7812383800 34 WASHINGTON STREET STE 310 WELLESLEY HILLS MA 02481 JEFFREY MORBY CO-CHAIRMAN 20.00 X X 0 0 0 HENRY MCCANCE CO-CHAIRMAN 5.00 X X 0 0 0 PHYLLIS RAPPAPORT TREASURER 2.00 X X 0 0 0 BILL BENTER DIRECTOR 2.00 X 0 0 0 ROBERT GREENHILL DIRECTOR 2.00 X 0 0 0 JAY JESTER DIRECTOR 5.00 X 0 0 0 JACQUELINE MORBY DIRECTOR 5.00 X 0 0 0 SHERRY SHARP DIRECTOR 2.00 X 0 0 0 TIMOTHY ARMOUR PRESIDENT & CEO 40.00 X X 258333 0 9408 MARGARET SMITH SECRETARY & SR VP 20.00 X 133719 0 5000 BARBARA CHAMBERS SENIOR VICE PRESIDENT 40.00 X 181416 0 15871 SALLY G ROSENFIELD SENIOR VICE PRESIDENT 40.00 X 167419 0 11467 JOHN SLATTERY SENIOR VICE PRESIDENT 40.00 X 178356 0 6798 KATHERINE HERMAN EXECUTIVE VICE PRESIDENT (AS OF 09/19) 40.00 X 148734 0 9019 1067977 0 57563 6 0 1 0 PROPER VILLIANS INC 668 STONY HILL RD YARDLEY MA 19067 CREATIVE SERVICES 227885 GRYPHON CONSULTING INC 21 DEAN ST BELMONT MA 02478 FINANCIAL & MGT CONSULTANT 171409 CHOATE HALL & STEWART TWO INTERNATIONAL PLACE BOSTON MA 02110 LEGAL FEES 120512 RUBENSTEIN 825 EIGHTH AVENUE NEW YORK NY 10019 STRATEGIC COMMUNICATIONS 120154 4 30497342 4985904 30497342 83306 83306 3995767 3993682 2085 2085 2085 30582733 0 0 85391 15431965 15431965 919763 919763 562913 326490 106953 129470 1291433 779604 225629 286200 34861 20970 6141 7750 93814 55796 16933 21085 134964 86192 21738 27034 120513 61670 35299 23544 162328 162328 107124 107124 40 40 889014 702877 70988 115149 103567 65838 37729 225712 69684 62593 93435 82712 6707 76005 185495 110212 33554 41729 239944 112165 36862 90917 555824 361607 51764 142453 11756 11756 15179 3812 11367 RESEARCH LAB EXPENSES 2936648 2936648 GIFT PROCESSING FEES 139534 159 139375 MISCELLANEOUS 62924 15922 14995 32007 24308027 22175046 945104 1187877 2352595 4437174 148396 1293996 785013 6309700 259681 65952 54458 27863 38351 26595 3996790 1321453 7580826 13454870 392536 143095 499053 409173 891589 552268 X 5466208 6344297 1223029 6558305 6689237 12902602 7580826 13454870 6274706 -61341 0 X 0 1 X 1 0 X 11248214 16220862 17501551 19798072 30497342 95266041 11248214 16220862 17501551 19798072 30497342 95266041 10624098 84641943 764 611 13021 77320 83306 175022 3150 90 3644 6884 95447947 0.88680 0.86580 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 0 0 0 0 0 1 107124 0 0 107124 0 PART II-B, LINE 1(G) A REGISTERED LOBBYIST CONTACTED VARIOUS CONGRESSIONAL LEGISLATORS FOR THE PURPOSE OF ENCOURAGING INCREASED FUNDING OF ALZHEIMER'S DISEASE RESEARCH BY THE FEDERAL GOVERNMENT. 54458 27863 26595 26595 ACCRUED EXPENSE 409173 409173 X 30521352 -61341 -61341 30582693 40 40 30582733 24307987 0 24307987 40 40 24308027 PART X, LINE 2: THE ORGANIZATION IS EXEMPT FROM INCOME TAXES AS A PUBLIC CHARITY UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE. MANAGEMENT BELIEVES THAT THE ORGANIZATION OPERATES IN A MANNER CONSISTENT WITH ITS TAX-EXEMPT STATUS AT BOTH THE STATE AND FEDERAL LEVEL. THE ORGANIZATION ANNUALY FILES IRS FORM 990- RETURN OF ORGANIZATION EXEMPT FROM INCOME TAX REPORTING VARIOUS INFORMATION THAT THE IRS USES TO MONITOR THE ACTIVITIES OF TAX-EXEMPT ENTITIES. THESE TAX RETURNS ARE SUBJECT TO REVIEW BY THE TAXING AUTHORITIES, GENERALLY FOR A PERIOD OF THREE YEARS AFTER THEY WERE FILED. THE ORGANIZATION CURRENTLY HAS NO TAX EXAMINATIONS IN PROGESS. 0 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM 0 0 GRANTS AWARDED ALZHEIMER'S DISEASE RESEARCH 919763 0 0 0 0 0 0 919763 0 919763 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM IDENTIFYING NOVEL EPIGENETIC BIOMARKERS OF HUMAN COGNITIVE AGING. 171875 CHECK EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM THERAPEUTIC MODULATION OF TREM2 ACTIVITY 150000 CHECK EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM ASSESSMENT OF ANTIBODY-BASED DRUG TRAFFICKING ACROSS THE BBB VIA SULL-MENINGES CONNECTIONS. 115000 CHECK EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM GENE EXPRESSION THROUGHOUT DEVELOPMENT OF PATHOLOGY IN APPKI MICE; EFFECTS OF HUMAN TAU AND AGEING. 195388 CHECK EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM UNDERSTANDING MOLECULAR BIOMARKER CHANGES IN ALZHEIMER'S DISEASE USING GENETICALLY-DEFINED MOUSE MODELS. 172500 CHECK EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM PATCH-SEQ ANALYSIS OF THE CHOROID PLEXUS EPITHELIAL CELL BARRIER IN HOMEOSTASIS AND IN AD 115000 CHECK 6 0 0 0 0 0 0 PART III ACCOUNTING METHOD: 1 AMYLYX 43 THORNDIKE ST CAMBRIDGE MA 02141 464600503 750000 PEGASUS CLINICAL STUDY OF AMX0035 IN ALZHEIMERS DISEASE; DRUG DEVELOPEMENT BETH ISRAEL DEACONESS MEDICAL CENTER 330 BROOKLINE AVENUE BOSTON MA 02215 042103881 501 (C)(3) 172500 UTILIZING FUNCTIONAL MAPS TO DISCOVER MICRO RNA'S IN AD BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON MA 02115 042312909 501 (C)(3) 345000 THE ROLE OF MFND-NEAURODEGENERATIVE CLEC7A+MICROGLIA IN AN AD MOUSE MODEL; TARGETING THE MICROBIOME AND MICROGLIA IN AD CARNEGIE MELLON UNIVERSITY 4400 FIFTH AVE PITTSBURGH PA 15213 250969449 501 (C)(3) 199013 CIRCUITS: INTERPRETING ALZHEIMER'S DISEASE-ASSOCIATED GENETIC VARIATION AT ENHANGER REGION BOSTON CHILDRENS HOSPITAL 300 LONGWOOD AVE BOSTON MA 02115 042774441 501 (C)(3) 298115 MICROGLIAL HETEROGENEITY AND TRANSCIPTIONAL STATE CHANGES IN ALZHEIMER'S DISEASE. COLUMBIA UNIVERSITY 710 WEST 168TH STREET 3RD FLOOR NEW YORK NY 10032 135598093 501 (C)(3) 83375 2019 FITZPATRICK PETRUCELLI: PT BASED STRUCTURAL AND FUNCTIONAL BIOLOGY OF TAUOPATHIES DUKE UNIVERSITY SCHOOL OF MEDICINE 324 BLACKWELL ST WASHINGTON BLDG DURHAM NC 27701 562247203 501 (C)(3) 91687 A NOVEL APOE MIMETIC THERAPEUTIC PEPTIDE CN-105 ATTENUATES AD PATHOLOGY AND IMPROVES FUNCATIONAL OUTCOMES IN A MURINE MODEL OF AD HARVARD COLLEGE 677 HUNTINGTON AVE BOSTON MA 02115 042103580 501 (C)(3) 250000 ASSESSING THE LINKS BETWEEN THE MS4A RISK GENESE, MICROGLIA, AND ALZHEIMER'S DISEASE HARVARD COLLEGE 677 HUNTINGTON AVE BOSTON MA 02115 042103580 501 (C)(3) 171523 ANALYTICAL AND STATISTICAL TOOLS FOR SEQUENCE ANALYSIS FOR ALZHEIMER'S DISEASE HARVARD COLLEGE 677 HUNTINGTON AVE BOSTON MA 02115 042103580 501 (C)(3) 172500 ACTIVATION OF THE 26S PROTEASOME FOR THE TREATMENT OF ALZHEIMER'S DISEASE HOUSTON METHODIST HOSPITAL FOUNDATION PO BOX 4384 HOUSTON TX 77210 760094743 501 (C)(3) 287500 UNCOVERING THE MOLECULAR MECHANISM OF SELECTED DRUG CANDIDATES DERIVED FROM SYSTEMATIC ALZHEIMER'S DRUG REPOSITIONING ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI BOX 1049 GUSTAVE L LEVY PLACE NEW YORK NY 10026 136171197 501 (C)(3) 150000 VGF, A NOVEL THERAPEUTIC EFFECTOR OF AD PATHOGENESIS AND PROGRESSION MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 041564655 501 (C)(3) 172500 IMAGING MICROGLIAL HOMEOSTASIS AND DISRUPTION P2RY12 RADIOTRACER DEVELOPMENT MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 041564655 501 (C)(3) 172443 DIRECT MIGRATION OF MYELOID CELLS FROM THE SKULL MARROW TO THE BRAIN THROUGH ANATOMICAL CHANNELS ADDING FUEL TO THE FILE IN AD MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 041564655 501 (C)(3) 115000 HUMAN 3D NEURO-VASCULAR INTERACTION AND MENINGEAL LYMPHATIC MODELS WITH APPLICATION TO AD MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 041564655 501 (C)(3) 250000 NEUROIMMUNE MOLECULAR IMAGING: REDEFINING THE LANDSCAPE OF OPPORTUNITIES IN AD MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 041564655 501 (C)(3) 300000 UNDERSTANDING HUMAN BRAIN RESILIENCE TO ALZHEIMER'S PATHOLOGY MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 041564655 501 (C)(3) 108726 AN INNOVATIVE STUDY OF THE PUPIL LIGHT REFLEX IN AD MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 041564655 501 (C)(3) 350000 TAU AND B-AMYLOID ARE INNATE IMMUNE ANTIMICROBIAL PEPTIDES IN THE BRAIN MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 041564655 501 (C)(3) 345000 INHIBITING CD33 FUNCTION AND MODULATING MICROGLIAL ACTIVATION STATE FOR ALZHEIMER'S DISEASE THERAPY MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 041564655 501 (C)(3) 287500 HIGH THROUGH PUT DRUG SCREENING FOR AD USING 3D HUMAN NEURAL CULTURE SYSTEMS MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 041564655 501 (C)(3) 172500 GENES TO THERAPIES CENTRALIZED RESEARCH CORE MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 041564655 501 (C)(3) 171914 INTERLEUKIN-3 IN AD MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 041564655 501 (C)(3) 250000 GUT MICROBIOME MEDIATED SHIFTS IN B-AMYLOID DEPOSITION IN A HUMANIZED AD MOUSE MODEL MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 041564655 501 (C)(3) 1475000 ALZHEIMER'S GENOME PROJECT MASSACHUSETTS INSTITUTE OF TECHNOLOGY 77 MASSACHUSETTS AVE CAMBRIDGE MA 02139 042103594 501 (C)(3) 100000 HUMAN 3D NEURO-VASCULAR INTERACTION AND MENINGEAL LYMPHATICS MODELS WITH APPLICATION TO AD MAYO CLINIC 200 FIRST ST SW ROCHESTER MN 55905 416011702 501 (C)(3) 172500 THE ROLE OF CLUSTERIN IN TAU PATHOLOGY MAYO CLINIC JACKSONVILLE 4500 SAN PABLO ROAD S JACKSONVILLE FL 32224 593337028 501 (C)(3) 172500 2019 FITZPATRICK PETRUCELLI: PT-BASE STRUCTURAL AND FUNCTIONAL BIOLOGY OF TAUOPATHIES. MEMORIAL SLOAN KETTERING CANCER CENTER PO BOX 27106 NEW YORK NY 10087 131924236 501 (C)(3) 150000 BIOCHEMICAL MAPPTING OF THE GSM BINDING SITE OF THE NOVEL PYRIDAZINE-DERIVED SMALL MOLECULE Y-SECRETASE MODULARS NEW YORK UNIVERSITY SCHOOL OF MEDICINE 550 1ST AVE R607 NEW YORK NY 10016 135562308 501 (C)(3) 250000 NEUROTOXIC REACTIVE ASTROCYES IN ALZHEIMER'S DISEASE NORTHWESTERN UNIVERSITY 633 CLARK STREET EVANSTON IL 60208 362167817 501 (C)(3) 115000 THE ROLE OF IMPAIRED SYNAPTIC VESICLE MACHINERY PROTEOSTATSIS IN ALZHEIMER'S DISEASE PATHOGENESIS NORTHWESTERN UNIVERSITY 633 CLARK STREET EVANSTON IL 60208 362167817 501 (C)(3) 250000 MOLECULAR AND CELLULAR MECHANISMS OF ACE1 R1279Q IN AD PALO ALTO VETERANS INSTITUTE FOR RESEARCH 3801 MIRANDA AVE 101-A2-210 PALO ALTO CA 94304 770207331 501 (C)(3) 172500 REJUVENATION OF MICROGLIA IN BRAIN AGING AND NEURODEGENERATION SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE 10901 N TORREY PINES RD LA JOLLA CA 92037 510197108 501 (C)(3) 172500 MECHANISMS FOR AD-ASSOCIATED DORLA MUTATIONS IN MICROGLIA AND NEURONS IN AD PATHOGENESIS THE BROAD INSTITUTE INC 415 MAIN ST CAMBRIDGE MA 02142 263428781 501 (C)(3) 750000 PRODUCTION CENTER FOR REFERENCE AND VARIATION GENE-REGULARTORY MAPS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 1111 FRANKLIN ST 12TH FLOOR OAKLAND CA 94607 943067788 501 (C)(3) 150000 TREATING WITH GAMMA-SECRETASE MODULATORS TO PREVENT NEAURDENERATION IN MOUSE MODELS OF DOWN SYNDROME AND AD THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 1111 FRANKLIN ST 12TH FLOOR OAKLAND CA 94607 943067788 501 (C)(3) 250000 INTERPRETATION OF NON-CODING RISK ALLELES OF AD THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 1111 FRANKLIN ST 12TH FLOOR OAKLAND CA 94607 943067788 501 (C)(3) 172500 HUMAN-SPECIFIC EVOLUTION OF CD33: EVOLUTIONARY RELATIONSHIP TO ANCIENT HOST-PATHOGEN INTERACTIONS AND CURRENT IMPLICATION FOR ALZHEIMER'S DISEASE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 1111 FRANKLIN ST 12TH FLOOR OAKLAND CA 94607 943067788 501 (C)(3) 150000 BIOCHEMICAL MAPPING OF THE GSM BINDING SITE OF THE NOVEL PYRIDAZINE-DERIVED SMALL MOLECULE Y-SECRETASE MODULATORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 1111 FRANKLIN ST 12TH FLOOR OAKLAND CA 94607 943067788 501 (C)(3) 287500 ALZHEIMERS DISEASE-ASSOCIATED MUTATIONS IN PROTEIN KINASE C THE ROCKEFELLER UNIVERSITY 1230 YORK AVENUE NEW YORK NY 10065 131624158 501 (C)(3) 172500 DISCOVERY OF CHEMICAL COMPOUNDS THAT INDUCE DEGRADATION OF APP-B-CTF IN CELLS THE ROCKEFELLER UNIVERSITY 1230 YORK AVENUE NEW YORK NY 10065 131624158 501 (C)(3) 150000 STIMULATING PROTEASOME ACTIVITY FOR THE TREATMENT OF AD THE SALK INSTITUTE FOR BIOLOGICAL STUDIES 10010 N TORREY PINES ROAD LA JOLLA CA 92037 952160097 501 (C)(3) 115000 IMPACT OF GENETIC, EPIGENETIC AND CELLULAR VARIANTS ON AD PATHOLOGY. THE TRUSTEES OF BOSTON UNIVERSITY 25 BUICK STREET BOSTON MA 02115 042103547 501 (C)(3) 172500 EVALUATION OF THE EFFECT OF CELL TYPE- SPECIFIC DELETION OF ESCRT GENES ON THE SPREAD OF TAU PATHOLOGY THE TRUSTEES OF BOSTON UNIVERSITY 25 BUICK STREET BOSTON MA 02115 042103547 501 (C)(3) 172500 AD PHARMACOMICS IN 3D THE UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN RIVE LA JOLLA CA 92093 952872494 501 (C)(3) 237500 IDENTIYING THE BLOOD BRAIN BARRIER CHANGES DURING AD THE UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN RIVE LA JOLLA CA 92093 952872494 501 (C)(3) 230000 THE EFFECT OF CHRONIC GAMMA-SECRETED MODULATION ON THE PREVENTION OF TBI-PROVOKED AND AD-RELEVANT BIOCHEMICAL PATHOLOGICAL AND BEHAVIORAL ALTERATIONS UNIVERSITY OF CONNECTICUT HEALTH CENTER 263 FARMINGTON AVE FARMINGTON CT 06030 237187838 501 (C)(3) 172500 PHYSIOLOGICAL METHOD FOR EARLY DETECTION OF SYNAPTIC VULNERABILITY IN AD MODEL ANIMALS UNIVERSITY OF CHICAGO 5235 S HARPER COURTH 4TH FLOOR CHICAGO IL 60615 362177139 501 (C)(3) 200000 IN VITRO AND IN VIVO ANALYSIS OF AN APP VARIANT UNIVERSITY OF RHODE ISLAND 75 LOWER COLLEGE RD STE 001 KINGSTON RI 02881 364644408 501 (C)(3) 56404 CEREBROVASCULAR DYSFUNCTION IN AD: TARGETING THE MECHANISMS OF VASCULAR ACTIVATION UNIVERSITY OF SOUTHERN CALIFORNIA UNIVERSITY PARK LOS ANGELES CA 90089 951642394 501 (C)(3) 172565 THE ROLE OF TREM2, APOE AND SEX UNIVERSITY OF SOUTHERN CALIFORNIA UNIVERSITY PARK LOS ANGELES CA 90089 951642394 501 (C)(3) 345000 MOLECULAR SIGNATURES OF APOE-MEDIATED BLOOD BRAIN BARRIER DYSFUNCTION CAUSING NEURONAL AND SYNAPTIC DYSFUNCATION UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER 5323 HARRY HINES BLVD DALLAS TX 75390 752556007 501 (C)(3) 172500 GENETIC TARGETS TO BLOCK TAU PROPAGATION: TEST KNOCKDOWN OF HSPG GENES IN VIVO WASHINGTON UNIVERSITY ST LOUIS 700 ROSEDALE AVE ST LOUIS MO 63112 430653611 501 (C)(3) 345000 ROLE IN MODULATING AB AND TAU-RELATED PATHOLOGIES AND NEURODENERATION WASHINGTON UNIVERSITY ST LOUIS 700 ROSEDALE AVE ST LOUIS MO 63112 430653611 501 (C)(3) 150000 TARGETING REACTIVE ASTOCYTES FOR THERAPEUTIC INTERVENTION OF AD WASHINGTON UNIVERSITY ST LOUIS 700 ROSEDALE AVE ST LOUIS MO 63112 430653611 501 (C)(3) 172500 MODELING AD IN SPECIFIC SUBTYPES OF HUMAN NEURONS THROUGH DIRECT NEURONAL REPROGRAMMING OF PATIENT FIBROBLASTS. WASHINGTON UNIVERSITY ST LOUIS 700 ROSEDALE AVE ST LOUIS MO 63112 430653611 501 (C)(3) 150000 STABLE ISOTOPE LABELING & QUANTITATIVE MASS SPECTOMETRY IMAGING OF AD PATHOLOGY IN HUMAN BRAIN WASHINGTON UNIVERSITY ST LOUIS 700 ROSEDALE AVE ST LOUIS MO 63112 430653611 501 (C)(3) 154701 CENTRAL CLOCK INFLUENCE ON ALZHEIMER'S DISEASE PATHOGENESIS WASHINGTON UNIVERSITY ST LOUIS 700 ROSEDALE AVE ST LOUIS MO 63112 430653611 501 (C)(3) 172500 HARNESSING BIG DATA TO UNDERSTAND AD RISK WASHINGTON UNIVERSITY ST LOUIS 700 ROSEDALE AVE ST LOUIS MO 63112 430653611 501 (C)(3) 103016 CHARACTERIZATION OF AD MOLECULAR BIOMARKER PROFILES THROUGHOUT THE PATHOBIOLOICAL CONTINUUM WASHINGTON UNIVERSITY ST LOUIS 700 ROSEDALE AVE ST LOUIS MO 63112 430653611 501 (C)(3) 345000 BERG BRAIN ENTRY & EXIT CONSORTIUM: CROSSTALK OF DNS BARRIERS AND CLEARANCE ROUTES IN HOMEOSTASIS AND AD WASHINGTON UNIVERSITY ST LOUIS 700 ROSEDALE AVE ST LOUIS MO 63112 430653611 501 (C)(3) 172497 THE CIRCADIAN CLOCK MODULATES NEURODENERATION IN AD VIA REVE-ERB WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY 1167 YORK AVE NEW YORK NY 10065 136094042 501 (C)(3) 173486 AD RISK IS HIGHER IN WOMEN: IDENTIFICATION OF FEMALE SPECIFIC BRAIN BIOENERGETIC TARGETS WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY 1167 YORK AVE NEW YORK NY 10065 136094042 501 (C)(3) 150000 REGULATION OF MIRCOGLIAL LYSOSOME ACIDIFICATION WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY 1167 YORK AVE NEW YORK NY 10065 136094042 501 (C)(3) 172500 DIETARY SALT TAU PHOSPHRYLATION AND COGNITIVE IMPAIRMENT WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH 9 CAMBRIDGE CENTER CAMBRIDGE MA 02142 061043412 501 (C)(3) 172500 IMPACT OF GENETIC, EPIGENETIC AND CELLULAR VARIANTS ON AD PATHOLOGY YALE UNIVERSITY 333 CEDAR ST NEW HAVEN CT 06510 060646973 501 (C)(3) 172500 ROLE OF MICROGLIAL PROTEIN SPARC IN CONTROL OF INFLAMMASOME ACTIVATION PART I, LINE 2: THE RESEARCH LEADERSHIP GROUP REVIEWS EACH PROPOSAL FOR FIT WITH THE CURE ALZ RESEARCH PORTFOLIO, SCIENTIFIC INTEGRITY, AND VALUE TO THE SEARCH FOR A CURE FOR ALZHEIMER'S DISEASE. ALL FUNDED RESEARCHERS MAY BE ASKED TO REVIEW OCCASIONAL PROPOSALS ON A THREE-WEEK TIMELINE AS A CONDITION OF RECEIVING FUNDING. THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS PROVIDES A FINAL REVIEW TO ENSURE ALL PROCEDURES HAVE BEEN FOLLOWED AND THAT PROPOSAL FITS WITHIN THE ORGANIZATION'S MISSION TO FUND RESEARCH CONTRIBUTING TO A CURE FOR ALZHEIMER'S DISEASE. AT LEAST TWO SCIENTIFIC REVIEWERS MUST SUBMIT A POSITIVE REVIEW FOR A PROPOSAL TO BE ACCEPTED. ANY QUESTIONS OR CONCERNS ABOUT THE PROPOSAL BY ANY REVIEWER MAY RESULT IN A REQUEST FOR ITERATION OR REJECTION OF THE PROPOSAL. RESEARCHERS WILL BE ADVISED OF ACCEPTANCE, QUESTIONS, OR REJECTION BUT WILL NOT RECEIVE ANY "SCORE OR ASSESSMENT COMMENTARY FROM REVIEWERS; HOWEVER, SUGGESTIONS OR IDEAS FROM REVIEWERS ARE SYNTHESIZED AND PROVIDED WITHOUT ATTRIBUTION IF A PROPOSAL IS FUNDED. X X X X 0 0 0 0 0 0 0 0 0 TIMOTHY ARMOUR PRESIDENT & CEO 258333 0 0 0 0 0 9408 0 0 0 267741 0 0 0 BARBARA CHAMBERS SENIOR VICE PRESIDENT 181416 0 0 0 0 0 7142 0 8729 0 197287 0 0 0 SALLY G ROSENFIELD SENIOR VICE PRESIDENT 167419 0 0 0 0 0 6782 0 4685 0 178886 0 0 0 JOHN SLATTERY SENIOR VICE PRESIDENT 178356 0 0 0 0 0 6798 0 0 0 185154 0 0 0 KATHERINE HERMAN EXECUTIVE VICE PRESIDENT (AS OF 09/1 148734 0 0 0 0 0 5074 0 3945 0 157753 0 0 0 X 77 4985904 SALE PRICE 0 0 0 1 PART I, LINE 32B: WHEN STOCK IS RECEIVED AS A CONTRIBUTION IT IS SOLD IMMEDIATELY UPON RECEIPT OR SOON THEREAFTER AS IS PRACTICAL THROUGH BANK OF NEW YORK/MELLON. FORM 990, PART VI, SECTION A, LINE 2 JEFFREY MORBY AND JACQUELINE MORBY ARE BOTH DIRECTORS AND SPOUSES. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS PREPARED BY THE EXTERNAL AUDITORS AND REVIEWED BY THE PRESIDENT AND CONTRACT CFO. REVISIONS, CORRECTIONS, ETC. ARE MADE AS NECESSARY. ONCE ALL ARE SATISFIED WITH THE FORM, IT IS FINALIZED AND A COPY IS SENT TO ALL BOARD MEMBERS. FORM 990, PART VI, SECTION B, LINE 12C EACH YEAR THE ORGANIZATION'S CONFLICT OF INTEREST POLICY IS PROVIDED TO ALL OFFICERS, DIRECTORS AND KEY EMPLOYEES. THESE PEOPLE ARE ASKED TO REVIEW THE POLICY AND SIGN A STATEMENT INDICATING THAT THEY UNDERSTAND THE POLICY AND HAVE REPORTED ALL POTENTIAL CONFLICTS DURING THE PAST YEAR IN ACCORDANCE WITH THE POLICY AND WILL REPORT ALL POTENTIAL CONFLICTS DURING THE COMING YEAR. ALL POTENTIAL CONFLICTS ARE EVALUATED BY THE BOARD TO DETERMINE IF A CONFLICT ACTUALLY EXISTS. IN THOSE INSTANCES WHERE THE POTENTIAL TRANSACTION IS A CONFLICT, THE BOARD EXAMINES THE TRANSACTION AND A VOTE IS TAKEN (WITH THOSE INVOLVED RECUSING THEMSELVES) AS TO WHETHER THE ORGANIZATION WILL ENTER INTO THE TRANSACTION. FORM 990, PART VI, SECTION B, LINE 15 COMPARABILITY DATA IS SUBMITTED ANNUALLY TO THE EXECUTIVE COMMITTEE FOR COMPENSATION APPROVAL FOR THE PRESIDENT AND ALL OTHER EMPLOYERS. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION'S GOVERNING DOCUMENTS AND CONFLICT OF INTEREST POLICY ARE AVAILABLE UPON REQUEST. THE ORGANIZATION'S FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST AND AT THE ORGANIZATION'S WEBSITE.